Correlation
The correlation between GMAB and VRTX is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
GMAB vs. VRTX
Compare and contrast key facts about Genmab A/S (GMAB) and Vertex Pharmaceuticals Incorporated (VRTX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GMAB or VRTX.
Performance
GMAB vs. VRTX - Performance Comparison
Loading data...
Key characteristics
GMAB:
-0.72
VRTX:
0.05
GMAB:
-0.83
VRTX:
0.09
GMAB:
0.89
VRTX:
1.01
GMAB:
-0.38
VRTX:
-0.09
GMAB:
-1.06
VRTX:
-0.23
GMAB:
22.58%
VRTX:
9.47%
GMAB:
33.22%
VRTX:
28.66%
GMAB:
-84.20%
VRTX:
-91.77%
GMAB:
-56.24%
VRTX:
-13.48%
Fundamentals
GMAB:
$13.11B
VRTX:
$114.53B
GMAB:
$1.70
VRTX:
-$3.83
GMAB:
1.11
VRTX:
2.65
GMAB:
4.06
VRTX:
10.32
GMAB:
2.47
VRTX:
6.93
GMAB:
$18.10B
VRTX:
$11.10B
GMAB:
$17.26B
VRTX:
$9.55B
GMAB:
$6.62B
VRTX:
-$76.30M
Returns By Period
In the year-to-date period, GMAB achieves a 2.16% return, which is significantly lower than VRTX's 11.02% return. Over the past 10 years, GMAB has underperformed VRTX with an annualized return of 9.30%, while VRTX has yielded a comparatively higher 13.43% annualized return.
GMAB
2.16%
2.55%
0.76%
-23.83%
-11.11%
-6.89%
9.30%
VRTX
11.02%
-11.20%
-3.76%
1.35%
17.77%
9.20%
13.43%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GMAB vs. VRTX — Risk-Adjusted Performance Rank
GMAB
VRTX
GMAB vs. VRTX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Genmab A/S (GMAB) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
GMAB vs. VRTX - Dividend Comparison
Neither GMAB nor VRTX has paid dividends to shareholders.
Drawdowns
GMAB vs. VRTX - Drawdown Comparison
The maximum GMAB drawdown since its inception was -84.20%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for GMAB and VRTX.
Loading data...
Volatility
GMAB vs. VRTX - Volatility Comparison
The current volatility for Genmab A/S (GMAB) is 11.29%, while Vertex Pharmaceuticals Incorporated (VRTX) has a volatility of 13.43%. This indicates that GMAB experiences smaller price fluctuations and is considered to be less risky than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
GMAB vs. VRTX - Financials Comparison
This section allows you to compare key financial metrics between Genmab A/S and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GMAB vs. VRTX - Profitability Comparison
GMAB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Genmab A/S reported a gross profit of 673.00M and revenue of 715.00M. Therefore, the gross margin over that period was 94.1%.
VRTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.41B and revenue of 2.77B. Therefore, the gross margin over that period was 86.9%.
GMAB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Genmab A/S reported an operating income of 188.00M and revenue of 715.00M, resulting in an operating margin of 26.3%.
VRTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported an operating income of 630.10M and revenue of 2.77B, resulting in an operating margin of 22.8%.
GMAB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Genmab A/S reported a net income of 195.00M and revenue of 715.00M, resulting in a net margin of 27.3%.
VRTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a net income of 646.30M and revenue of 2.77B, resulting in a net margin of 23.3%.